Budesonide Suspension
Product Images NDC 50090-6586

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 50090-6586). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906586)

Budesonide Inhalation Suspension 0.5 mg/2 mL label from A-S Medication Solutions. The label indicates a single-dose ampule format with 30 ampules per carton, intended for respiratory inhalation. It includes lot number, storage instructions to avoid heat and light, and the product's National Drug Code (50090-6586).*

FDA Label Image

Spl-budesonide-fig-1 (Spl Budesonide Fig 1)

A line graph titled 'Nighttime Asthma Change from Baseline' from a 12-week trial in pediatric patients not on inhaled corticosteroid therapy. The y-axis shows mean change from baseline nighttime asthma symptoms, ranging from 0.0 to -0.6. The x-axis represents time intervals from baseline through weeks 0-12. Four lines depict treatments: placebo, 0.25 mg once daily, 0.5 mg once daily, and 1 mg once daily. The graph shows symptom changes over time with p-values for treatment groups provided below the figure.*

FDA Label Image

Spl-budesonide-fig-2 (Spl Budesonide Fig 2)

A line graph titled 'Nighttime Asthma Change from Baseline' illustrating mean change from baseline nighttime asthma symptoms over a 12-week trial in pediatric patients on inhaled corticosteroid therapy. The graph compares placebo, 0.25 mg twice daily, and 0.5 mg twice daily doses, showing symptom changes from baseline at weeks 0-12. P-values for 0.25 mg and 0.5 mg doses are noted.*

FDA Label Image

Spl-budesonide-fig-3 (Spl Budesonide Fig 3)

A line graph titled 'Nighttime Asthma Change from Baseline' showing mean change in baseline nighttime asthma symptoms over a 12-week trial in pediatric patients. The x-axis represents time intervals from baseline to weeks 10-12, and the y-axis shows the mean change from baseline. Multiple lines track different treatments: placebo, 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg once daily, indicating changes in asthma symptoms during the study period.*

FDA Label Image

Spl-budesonide-fig-4 (Spl Budesonide Fig 4)

An illustration showing two hands holding a strip of five single-use ampules labeled "STERILE For oral inhalation only." Each ampule has printed fields for batch number (B.No:) and expiration date (Exp:). The top of the ampules is marked with the brand name "SUN PHARMA."*

FDA Label Image

Spl-budesonide-fig-5 (Spl Budesonide Fig 5)

Instructional illustration showing a hand twisting the cap off a sterile vial labeled 'For oral inhalation only' containing Budesonide suspension. The illustration includes a bold curved arrow indicating the direction to twist the cap, with areas marked for batch number and expiration date.*

FDA Label Image

Spl-budesonide-fig-6 (Spl Budesonide Fig 6)

An instructional illustration showing hands opening a Budesonide respiratory suspension vial by twisting the top cap. The vial label indicates the product is for oral inhalation only. Black arrows illustrate the twisting motion required to open the vial cap.*

FDA Label Image

Spl-budesonide-fig-7 (Spl Budesonide Fig 7)

An instructional line drawing showing two hands using a small vial labeled 'STERILE For oral inhalation only' to dispense a drop of suspension into a handheld inhalation device with a mouthpiece and a handle. The illustration demonstrates preparation of a budesonide respiratory suspension dose for inhalation.*

FDA Label Image

Spl-budesonide-str (Spl Budesonide Str)

Chemical structure of Budesonide, showing its steroid backbone with multiple hydroxyl groups, methyl substituents, and characteristic functional groups including ketones and an ether bridge.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.